Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes (B-LIFT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06035874 |
Recruitment Status :
Recruiting
First Posted : September 13, 2023
Last Update Posted : January 5, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions ranging from liver steatosis (NAFL), steatohepatitis (NASH), advanced liver fibrosis and ultimately leads to cirrhosis in a significant proportion of individuals. NAFLD is intimately associated with insulin resistance and associated disorders, such as type 2 diabetes, metabolic syndrome and dyslipidemia.
Bempedoic acid, an ATP-citrate lyase inhibitor, is recently approved for patients with dyslipidemia as a second line drug. Bempedoic acid reduces liver fat in mice model of NASH. Data regarding the effect of bempedoic acid on human liver fat are scarce. Therefore, the current study is planned to evaluate the effect of bempedoic acid versus standard treatment on liver and pancreatic fat content in patients with NAFLD
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Type 2 Diabetes Non Alcholic Fatty Liver Disease | Drug: Bempedoic acid | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Randomized Controlled Trial |
Actual Study Start Date : | October 15, 2023 |
Estimated Primary Completion Date : | November 1, 2024 |
Estimated Study Completion Date : | December 1, 2024 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Bem group
Patient will get Bempedoic acid along with the standard of Care
|
Drug: Bempedoic acid
Patient willl be randomized 1:1 in both the arms |
No Intervention: Control Group
Patient will get the standard of Care as per routine practice
|
- The change in liver fat content [ Time Frame: Baseline to 24 Weeks ]The primary outcome measure will be the difference of the change in liver fat content from 0 (baseline) to 24 weeks between groups
- The change in pancreatic fat [ Time Frame: Baseline to 24 Weeks ]The difference of the change in pancreatic fat content from 0 (baseline) to 24 weeks between groups. [Pancreatic fat content as quantified by MRI PDFF]
- The change in controlled attenuation parameter [ Time Frame: Baseline to 24 Weeks ]The difference of the change in controlled attenuation parameter (CAP) from 0 (baseline) to 24 weeks between groups. [CAP will be assessed by transient elastography].
- The change in liver stiffness measurement (LSM) [ Time Frame: Baseline to 24 Weeks ]The difference of the change in liver stiffness measurement (LSM) from 0 (baseline) to 24 weeks between groups. [LSM will be measured by transient elastography].
- Change between the groups in aspartate aminotransferase (AST) levels [ Time Frame: Baseline to 24 Weeks ]Change between the groups in aspartate aminotransferase (AST) levels
- Change between groups in alanine aminotransferase (ALT) levels [ Time Frame: Baseline to 24 Weeks ]Change between groups in alanine aminotransferase (ALT) levels
- Change between groups in gamma-glutamyl transpeptidase (GGT) levels. [ Time Frame: Baseline to 24 Weeks ]Change between groups in gamma-glutamyl transpeptidase (GGT) levels.
- Change between the groups in serum creatinine concentrations. [ Time Frame: Baseline to 24 Weeks ]Change between the groups in serum creatinine concentrations.
- Change between the groups in total cholesterol levels. [ Time Frame: Baseline to 24 Weeks ]Change between the groups in total cholesterol levels.
- Change between groups in triglycerides levels. [ Time Frame: Baseline to 24 Weeks ]Change between groups in triglycerides levels.
- Change between groups in LDL levels [ Time Frame: Baseline to 24 Weeks ]Change between groups in LDL levels
- Change between groups in HDL levels [ Time Frame: Baseline to 24 Weeks ]Change between groups in HDL levels
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
A man or woman, 20 years of age or above with the diagnosis of type 2 diabetes for at least 3 months who meets all the following two criteria:
- On standard anti-diabetic agents (metformin, DPP-4 inhibitors, sulphonylureas or insulin, in any combination) with an HbA1c of <9% at screening
- Have documented hepatic steatosis (MRI-PDFF >5.6%) on screening MRI- PDFF
- Participants must be medically stable based on medical history, physical examination and laboratory investigations.
- Participants must be willing and able to adhere to the prohibitions and restrictions specified in this protocol.
- Each participant must sign an informed consent form (ICF) indicating that he or she understands the purpose of the study and are willing to participate in the study.
Exclusion Criteria:
- History of diabetic ketoacidosis, type 1 diabetes, pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy.
- History of brittle or labile glycemic control, with widely varying glucose measurements by FPG or SMBG such that stable glucose control over the treatment period would be unlikely.
- History of drug or alcohol abuse according to Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-V) criteria within 3 years before Screening, or an Alcohol Use Disorders Identification Test (AUDIT) with a score >8, or alcohol consumption of more than 20 g per day in the case of women and more than 30 g per day in the case of men for at least three consecutive months during the previous 5 years.
- Thyroid stimulating hormone (TSH) value that is either < 0.45 mIU/L or >10 mIU/L at Screening. Note: Subjects on thyroid hormone replacement therapy must be on a stable dose and dosing regimen for at least 4 weeks prior to enrollment.
- Use of a PPAR-γ agonist [e.g., a thiazolidinedione (pioglitazone], an SGLT2 inhibitor (e.g., canagliflozin, empagliflozin, dapagliflozin), GLP-1 receptor agonists (e.g., liraglutide, dulaglutide) or saroglitazar (Dual PPARα/γ agonist) within 12 weeks before the enrollment.
- BMI >40 kg/m2.
- Ongoing eating disorder, or a significant weight loss or weight gain within 12 weeks before the Screening visit, defined as an increase or decrease of 5% in body weight based upon clinic-based measurement or, if not available, based on subject's report.
- Use of weight loss medication (prescription and/or over the counter) within 3 months prior to Screening or have participated in a weight loss/diet program within 12 months prior to Screening.
- Renal disease that required treatment with immunosuppressive therapy or a history of dialysis or renal transplant.
- Myocardial infarction, unstable angina, pulmonary hypertension, revascularization procedure (e.g., stent or bypass graft surgery), or cerebrovascular accident within 3 months before Screening, or revascularization procedure is planned, or subject has a history of New York Heart Association (NYHA) Class III-IV cardiac disease.
- History of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease, or tests positive for HBsAg or anti- HCV at Screening.
- Use of vitamin E within 12 weeks before screening.
- History of prior bariatric (e.g., Roux-en-Y gastric bypass) or other major upper gastrointestinal surgical procedure (including gastric resection).
- History of diabetic gastroparesis (or symptoms suggestive of this disorder, including postprandial bloating or vomiting), malabsorption, inflammatory bowel disease, or any other chronic, clinically important gastrointestinal disorder.
- Estimated glomerular filtration rate (eGFR) <60 mL/min/1•73 m2 using the Modification of Diet in Renal Disease Study (MDRD) equation.
- Subjects with a history of having or possibly having metallic material in the body or any contraindication for a MR examination.
- Claustrophobia, or anxiety related to previous negative experiences with magnetic resonance imaging procedures or if the subject is unwilling to participate in magnetic resonance imaging procedures.
- Clinically important hematologic disorder (e.g., symptomatic anemia, proliferative bone marrow disorder, thrombocytopenia) at Screening.
- History of human immunodeficiency virus (HIV) antibody positive at Screening.
- Major surgery (e.g., requiring general anesthesia) within 12 weeks before Screening, or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study.
- Contraindications to the use of bempedoic acid (per BEMPEDOIC ACID Prescribing Information).
- Current use of a corticosteroid medication or immunosuppressive agent, or likely to require treatment with a corticosteroid medication or an immunosuppressive agent.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06035874
Contact: Mr Surender, PhD | 01244141414 ext 6596 | yadavsurender89@gmail.com |
India | |
Division Of Endocrinology , Medanta The Medicity Sec 38 | Recruiting |
Gurgaon, Haryana, India, 122001 | |
Contact: Mohammad S kuchay, MBBS, MD 0124-4141414 ext 6596 drshafikuchay@gmail.con | |
Contact: Surender Rao, Msc 0124-4141414 ext 6596 yadavsurender89@gmail.com |
Responsible Party: | Dr Mohammad Shafi Kuchay, Senior Consultant, Division of Endocrinology & Diabetes, Medanta, The Medicity, India |
ClinicalTrials.gov Identifier: | NCT06035874 |
Other Study ID Numbers: |
B-LIFTMED001 |
First Posted: | September 13, 2023 Key Record Dates |
Last Update Posted: | January 5, 2024 |
Last Verified: | January 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Liver Diseases Fatty Liver Non-alcoholic Fatty Liver Disease Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Digestive System Diseases |
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Enzyme Inhibitors Hypoglycemic Agents Physiological Effects of Drugs |